1403 - Lung Microwave Tissue Ablation

Page last updated: 20 July 2017

Application Detail

Status

Open

Description of Medical Service

NON-RESECTABLE PRIMARY LUNG CANCER AND PULMONARY METASTATIC DISEASE, destruction of, by percutaneous microwave tissue ablation (MTA), including any associated imaging services. Under multidisciplinary assessment, MTA is conducted in the following circumstances: Surgical resection is not possible due to the presence of lesions in unresectable locations, the number and anatomical distribution, poor cardiopulmonary function and/or other comobidities. Stereotactic body radiation therapy (SBRT) is not available or contraindicated. In conjunction with lung resection, chemotherapy, radiotherapy or other cancer treatments.

Description of Medical Condition

MTA is primarily targeted at the 15% of all patients and 30% of patients aged over 75 years with early stage NSCLC who are not candidates for surgical resection (Dupuy 2013). This ablation modality may also be used in patients with pulmonary metastases, where number and site of metastases, or previous lung surgery, precludes them from (further) surgery (Hiraki 2012).

Reason for Application

New MBS item

Medical Service Type

Therapeutic

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

Final Protocol (PDF 5806 KB)
Final Protocol (Word 1179 KB)

Assessment Report

Final Contracted Assessment Report (PDF 4107 KB)
Final Contracted Assessment Report (Word 4183 KB) (Word 4182 KB)

Public Summary Document

Public Summary Document (PDF 240 KB)
Public Summary Document (Word 111 KB)

Meetings for this Application

PASC

13 August 2015

ESC

6 - 7 October

MSAC

24 - 25 November 2016